Following the good results obtained with its Staby^TM technology in 2009 (scientifically and commercially), Delphi Genetics SA strengthens its commercial activity and modifies its executive leadership: Dr. Philippe Gabant becomes now the head of Business Development and Dr. Cedric Szpirer will be appointed as Chief Executive Officer.
Philippe Gabant and Cedric Szpirer are two of the co-founders of the company with Michel Milinkovitch and the University of Brussels (ULB).
In 2009, Delphi Genetics announced that the company had entered into an agreement with Sanofi Pasteur for the introduction of Delphi’s patented StabyExpress^TM technology into the manufacturing of human vaccines. Other non-exclusive license agreements are now in discussion. Delphi Genetics recently made new scientific discoveries which are very promising for the future.